The University of Michigan is enrolling for the BE UNIQUE study. This study aims to help us understand why some people with psoriasis have fast and long-lasting changes in their skin when using the study drug.
Our team will compare changes in your skin before and after taking bimekizumab. It will also be exploring whether extending the time between doses makes a difference in long-term responses to the study drug.
Eligible participants will
- Receive bimekizumab, a medication that is already prescribed in the US for plaque psoriasis and psoriatic arthritis
- Be monitored over 18 visits for potential side effects, changes in skin, pain, and quality of life
- Provide several skin biopsies and blood draws throughout the study
- Receive the study drug and study-related care at no charge, and compensation is provided for travel/participation
- Agree to discontinue current treatment
If someone you know is 18+ with psoriasis and a candidate for systemic therapy, they may qualify for this.